Care through discovery
Our multi-disciplinary teams of basic and translational, clinical, and health services scientists work with cutting-edge technology platforms in an environment that strives for innovation, creativity and new ways of thinking.
Research at The Institute is informed by everyday clinical challenges faced by Manitoba oncologists, and our overriding goal is to positively impact the lives of cancer patients and their families.
Clinical Trials
Tomorrow's treatment today
Clinical trials, research studies that test a medical intervention in people, are essential to advancing cancer care and the primary way scientists determine if a new form of detection, treatment, or support offers advantages over the current standard.
Each year about 300 Manitoban cancer patients are enrolled in approximately 120 clinical trials at CCMB, while thousands remain in long-term follow-up.
The Manitoba Tomorrow Project
Let’s change the course of cancer
The Manitoba Tomorrow Project is part of a 50-year nationwide research initiative, one of the largest studies ever undertaken to advance our knowledge about cancer and other chronic diseases – and you can help!
We need people ages
30-74 to sign up.
Research News
November 17, 2023
$17 million lab renovation enables research creativity and innovation
A major donation from the Paul Albrechtsen Foundation facilitates the transformation of 20-year-old research laboratories into state-of-the-art facilities housing cutting-edge technology and leading scientists pursuing the next cancer breakthroughs.
October 11, 2023
New book from Institute researcher, Dignity in Care: The Human Side of Medicine helps shape the future of patient care
Senior Scientist at CancerCare Manitoba Research Institute, Dr. Harvey Max Chochinov has published a new book, Dignity in Care: The Human Side of Medicine, providing insight into how the disposition and attitude of healthcare providers indelibly shape patient experience.
September 6, 2023
New trial looks at reducing bleeding risk in cancer patients while also developing novel research methods
A new Investigator-Initiated Clinical Trial (IICT) led by Primary Investigator, Dr. Brett Houston, called the MYELO-CAN TXA trial, aims to see whether Tranexamic Acid (TXA) can help prevent bleeding in patients with certain blood cancers such as acute leukemia and myelodysplastic syndrome.
;
It’s an exciting time @cancercare_mb_news. New scientists have joined the team at the Paul Albrechtsen Research Institute. These scientists are working on new and innovative research thanks to an incredible gift from the Paul Albrechtsen Foundation and your continued support.
Sandra Hajlo, the first person in Manitoba to receive CAR T-cell therapy, is now sharing her remarkable journey. Watch her inspiring story alongside Dr. David Szwajcer, Manitoba Blood & Marrow Transplant Director, on Manitoba’s first CAR-T patient.
Congratulations Dr. @HMChochinov Wonderful news!
Exciting to be included #AIMS project grantee @AtomwiseInc @nature Scientific Reports w/Senior technician Extrordinare Cheryl Peltier: AI is a viable alternative to HTS- @um_research @CancerCareMBFdn @CCMB_Research
Congratulations Cédric, Scientist at Paul Albrechtsen Research Institute CancerCare Manitoba, University of Manitoba
Join us for Cancer Day for Primary Care on May 31! Submit your own case for discussion by our expert panel. Register now https://tinyurl.com/h2eyhb2t
